Although inflammatory bowel disease is associated with higher risk of colorectal cancer, the precise pathogenic mechanisms underlying this association are not completely understood.
Introduction
Inflammatory bowel disease (IBD) includes two major chronic intestinal disorders, Crohn's disease and ulcerative colitis (UC), which share related characteristics such as mucosal damage and diarrhea but have distinguishing clinical features. Evidence suggests that in addition to the widely accepted aberrant mucosal immune response, non-immune cells including epithelial cells play an emerging role in the pathogenesis of disease by modulating mucosal barrier integrity and homeostasis (1) . An association between IBD and colorectal cancer (CRC) has been well established with a cumulative risk of developing CRC of 7% after 20 years for UC and 8% for Crohn's disease (2) . Previous studies have shown that production of proinflammatory cytokines in the lamina propria contribute to tumor growth and cancer development during intestinal inflammation (3, 4) . Prohibitin 1 (PHB) is an evolutionarily conserved, multifunctional 32 kDa protein implicated in cellular processes including the regulation of cell cycle progression, apoptosis, and transcription (5) (6) (7) . Expression of PHB is decreased in mucosal biopsies from ulcerative colitis and Crohn's disease afflicted patients and in the dextran sodium sulfate (DSS) and IL-10 -/-mouse models of colitis (8, 9) . Pro-inflammatory cytokines such as tumor necrosis factor α (TNFα) and reactive oxygen species decrease expression of intestinal epithelial PHB in vivo and in vitro (8) (9) (10) . Restoration of colonic epithelial PHB expression using genetic manipulation (villin-PHB transgenic mice) or therapeutic delivery to the colon via nanoparticles or adenovirus protected mice from experimental colitis (11, 12) .
The role of PHB in cancer cell proliferation and/or tumor suppression remains controversial especially since PHB expression is increased in many transformed cells and tumors 4 (13) (14) (15) (16) (17) (18) (19) . Consensus binding sites for the oncoprotein Myc are present in the PHB promoter and likely contribute to the increased PHB levels in many tumors (20) . Although somatic mutations in the PHB gene were observed in a few sporadic breast cancers, none were identified in the ovary, hepatic, or lung cancers examined (16) . Previous studies have shown that PHB has an anti-tumorigenic role in gastric, prostate, and liver cancers (21) (22) (23) . Despite the increasing number of studies on PHB, its role in colorectal cancer or colitis-associated cancer (CAC) has not been explored. Here, we used mice specifically overexpressing PHB in intestinal epithelial cells (IECs) to assess the role and mechanism of PHB in CAC.
Materials and methods
Animal models. Wild-type (WT) and villin-prohibitin transgenic (Tg) mice specifically overexpressing prohibitin in intestinal epithelial cells (12) were 9 wk old at the beginning of the experimental protocol. All mice were grouped-housed in standard cages under a controlled temperature (25˚C) and photoperiod (12-hour light /dark cycle) and were allowed standard chow and tap water ad libitum. All experiments were approved by the Baylor Research Institute Institutional Animal Care and Use Committee.
Induction of colitis-associated cancer in mice.
Age-matched male and female C57BL/6 WT and Tg mice were i.p. injected with 7.6 mg/kg azoxymethane (AOM; Sigma-Aldrich, St. Louis, MO) on day 0. Colitis was induced 7 days after AOM injection by oral administration of 3% (wt/vol) dextran sodium sulfate (DSS; molecular weight, 50,000; MP Biomedicals, Solon, OH) in drinking water ad libitum for 7 days followed by 14 days of recovery of water alone. After recovery, a second cycle of DSS was repeated and mice were sacrificed after 3 weeks of recovery (day 56) as previously described (24) . Three separate groups of mice were used as controls: one group of mice was maintained with regular water (n = 16 WT; n = 10 Tg), a second group of mice was injected with AOM and given water for the remainder of the experiment (n = 9 WT; n = 7 Tg), and the third group of mice was treated with DSS as described above without AOM injection (n = 20 WT; 8 Tg). AOM alone represents treatment with the alkylating agent in the absence of inflammation and is expected to result in no tumor formation in wild-type mice at the dose used (25) . DSS alone represents repeated cycles of inflammation and was included to assess whether inflammation alone caused dysplasia in these mice. The study was powered in such a fashion that the control arms required less mice since death prior to the end of the study was not anticipated for these treatment groups. Body weight, stool consistency, and stool occult blood was monitored during the DSS treatment and recovery phases. Upon sacrifice, colon was excised from the ileocecal junction to anus, cut open longitudinally, and prepared for histological evaluation.
To assess mortality, the same protocol was followed with the exception of extending through 126 days or until mice developed rectal prolapse and/or >20% body weight loss. Colons were assessed macroscopically for polyps using a dissecting microscope.
Clinical score assessment. Assessment of body weight loss, stool consistency, and the presence of occult/gross blood by a guaiac test (Hemoccult Sensa; Beckman Coulter, Fullerton, CA) were determined daily during DSS administration to generate a clinical activity score as described previously (12) . During recovery periods, body weight was measured every week for each group.
Endoscopic assessment of polyp formation and polyp count. Colonoscopy was done to assess polyp formation in mice by using the Coloview (Karl Storz Veterinary Endoscopy, Tuttlingen, Germany). Mice were euthanized with 1.5% -2% isoflurane and ~3 cm of the colon proximal to the anus was visualized after inflation of the colon with air. Mice were then sacrificed by cervical dislocation after euthanizing with isoflurane. Colon was excised from ileocecal junction to anus, washed with 0.9% NaCl, cut open longitudinally and preserved in 10% neutral buffered formalin. The number and size of the polyps were determined using a Jenko dissecting microscope.
Histopathology scoring. Colons fixed in 10% neutral buffered formalin were Swiss-rolled, embedded in paraffin, sectioned at 5 μm, and stained with H&E for histopathological examination of polyps and adenocarcinoma (neoplasia). Scoring was performed in a blind fashion by two qualified pathologists. Score was given based on these criteria: normal (score 0), low grade dysplasia (score 1), high grade dysplasia (score 2), intramucosal adenocarcinoma (score 3), and invasive adenocarcinoma (score 4).
Immunohistochemistry. 5-μm paraffin-embedded sections of colon were analyzed for Ki67 staining as a marker of cell proliferation as previously described (12) . A minimum of 15 crypts with normal morphology were counted for Ki67-positive cells per section.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining.
Immunofluorescent TUNEL staining was performed to measure apoptosis from paraffinembedded sections using the In Situ Cell Death Detection kit as described by the manufacturer (Roche, Indianapolis, IN). Nuclei were stained with 4, 6'diamidino-2-phenylindole (DAPI) to count total cells per crypt. A minimum of 10 crypts with normal morphology were counted per section. p53 mutational analyses. Tumor tissue was microdissected from paraffin-embedded sections (7 μm) of Swiss-rolled mouse colon. Genomic DNA was isolated from microdissected tissues using the QIAamp DNA FFPE Tissue purification kit (Qiagen, Valencia, CA). The PCR amplicons were generated and sequenced as previously described (26 Total RNA extraction and quantitative real-time PCR. Total RNA was extracted for human tissues using the RNeasy kit (Qiagen). Quantitative real-time PCR was performed as described previously (11) . See Supplementary Materials and Methods section for primer sequences.
Cell culture and transfection. Caco2-BBE cells were used to assess the interaction of PHB with STAT3. Since Caco2-BBE cells have mutated p53, wild-type (WT) HCT116 human colorectal cancer cells were utilized to assess PHB interaction with p53. All cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA). Cells were grown and transfected as previously described (27) . Mucosal strippings from Tg and WT mice were obtained for Western blot analysis as described previously (12) . Total protein was isolated from cultured cells as described previously (27) . Previous studies have shown that PHB has an anti-tumorigenic role in gastric, prostate, and liver cancers (21) (22) (23) . We used the AOM DSS mouse model to study the role of PHB in CAC. Body weight was measured weekly as one parameter to assess the severity of disease. WT and Tg mice given water only throughout the experiment and mice injected with AOM followed by water alone showed similar body weight gain over the 8-week protocol (Supplemental Figure   1A ) and did not develop polyps as previously reported for this dose of AOM (25) . WT mice given 2 cycles of DSS without AOM injection lost more body weight following DSS administration and recovered less weight compared to Tg mice over the 8-week protocol (Supplemental Figure 1B) , similar to our previous findings (12) . Although both WT and Tg AOM DSS-treated mice lost weight after the first administration of DSS, Tg mice gained body weight more rapidly during the recovery phase and maintained body weight better than WT mice throughout the remainder of the study ( Figure 1A ). Figure 1D ). Upon sacrifice the entire colon from ileocecal junction to anus was excised and assessed for number and size of polyps.
Tg mice showed considerably fewer polyps with the majority being smaller than 3 mm in diameter compared to WT mice ( Figure 1D ). Figure 1E shows representative photos of excised colons and endoscopic images of polyp formation in WT and Tg mice following AOM-DSS treatment. After polyps were counted and measured, colons were Swiss-rolled and assessed for histopathological score by a trained pathologist. WT mice had a higher occurrence of high grade dysplasia and adenocarcinoma compared to Tg mice which exhibited more low grade dysplasia and normal morphology ( Figure 1F ). Collectively, these results suggest that PHB Tg mice show less susceptibility to CAC than WT mice.
PHB Tg mice are less susceptible to CAC and mortality.
To assess mortality and cancer development, the same protocol was followed with the exception of extending through 126 days or until mice developed rectal prolapse and/or >20% body weight loss. WT mice showed greater mortality than Tg mice throughout the study. The difference in mortality was especially pronounced after the formation of polyps which occurs at approximately 8 weeks (Supplemental Figure 2A) . Tg mice showed significantly less total number of polyps, and although rare, a significantly less number of large polyps (>6 mm in diameter) compared to WT mice (Supplemental Figure 2B ). Mice that survived from 8 through 18 weeks were assessed for histopathological score since animals that died prior to 8 weeks did Figure 2C , the majority of WT mice developed adenocarcinoma (invasive adenocarcinoma: n = 2, intramucosal adenocarcinoma: n = 7) compared to 5 Tg mice (intramucosal adenocarcinoma). The majority of Tg mice had lowgrade or high-grade dysplasia. Supplemental Figure 2D shows representative gross anatomy of colon from three WT and Tg mice, which also reflects the number and size of polyps. These findings suggest that IEC-specific PHB overexpression improves mortality associated with CAC.
IEC-specific PHB overexpression does not affect cell proliferation during CAC.
Alteration in cell proliferation can contribute to tumorigenesis (29) . Ki67 immunohistochemical staining and proliferating cell nuclear antigen (PCNA) were assessed to examine the effect of PHB overexpression on cell proliferation in CAC. Both WT and Tg mice showed increased Ki67 staining following AOM-DSS treatment ( Figure 3A Given the effect of PHB overexpression on apoptosis during CAC, we examined levels of p53, a tumor suppressor, and its downstream targets p53 upregulated modulator of apoptosis (PUMA) and Bax as well as the activation of the pro-apoptotic protein Bad. p53 regulates cell survival through induction of cell cycle arrest or apoptosis. Our previous study showed that PHB protein levels are decreased in mucosal biopsies of active inflammation from Crohn's disease afflicted patients and in the DSS and IL-10 -/-mouse models of colitis (9) . To determine whether mucosal PHB levels are affected during CAC, Western blot analysis was performed on total protein isolated from mucosal stippings from WT mice. Figure 3A shows that mucosal PHB protein levels were decreased in WT mice after AOM DSS treatment compared to water control WT mice (water = 1.0 ± 0.09 vs. AOM DSS = 0.75 ± 0.06, P < 0.05). Tg mice exhibited higher expression of mucosal PHB protein levels compared to WT mice when given water or AOM DSS treatment ( Figure 3A) . Mucosal PHB protein expression in Tg mice was similar to our previous studies utilizing these animals (12) . Although induction of CAC increased p53 protein expression in both WT and Tg mice compared to water control mice, p53 levels were significantly higher in Tg mice compared to WT mice after AOM DSS treatment ( Figure 3B ). Quantitative real-time PCR analysis of total RNA isolated from mucosal samples from patients with inflamed ulcerative colitis (UC) or UC-associated adenocarcinoma/dysplasia revealed that PHB expression is significantly decreased compared to matched normal samples ( Figure 6 ). p53 expression was increased in inflamed UC and UC-associated dysplasia tissues, however this increase did not achieve statistical significance in the inflamed tissue samples.
STAT3 expression was markedly increased in inflamed UC and UC-associated dysplasia but did not achieve statistical significance.
Discussion
The specific mechanism by which IBD leads to CRC is poorly understood, but it is clear chronic mucosal inflammation plays a causative role in the transition to adenocarcinoma. Our previous studies have shown that restoration of mucosal PHB can ameliorate experimental colitis (11, 12) . For this reason, we chose to use the AOM DSS model to assess the role of PHB in CAC. Here, we show that in mice with CAC, IEC-specific PHB overexpression suppresses colonic neoplastic formation in association with increased rates of apoptosis. IEC-specific overexpression of PHB was associated with altered levels of p53, PUMA, Bax, p-Bad, Bcl-xL and Bcl-2 during CAC. We show, for the first time, that PHB interacts with phospho-STAT3 in addition to p53 in human colon cancer cells and colon mucosa, thereby modulating the apoptotic response ( Figure 7 ).
IBD patients with longstanding colitis require surveillance colonoscopy after 8 years of disease duration due to the high risk of cancer development (34) . Several features make colitisassociated cancer distinct from sporadic colon cancer. Colitis-associated cancer is often anaplastic, broadly infiltrating, rapidly growing, develops in flat dysplastic tissue, and occurs at a younger age. While genetic alterations are similar to those in sporadic colon cancer, the frequency and sequence of these events differ in colitis-associated cancer (35) . Loss of p53 function is an early critical event in colitis-associated neoplasia in humans in the pathway from dysplasia to cancer (36) . Furthermore, aberrent IL-6/STAT3 signaling is associated with inflammatory bowel disease and colitis-associated cancer (33) . Activated STAT3 is enhanced in CRC patients and has been shown to induce the anti-apoptotic proteins Bcl-2 and Bcl-xL (37).
Inhibition of STAT3 signaling induces apoptosis of colorectal cancer cells via the mitochondrial pathway by modulating Bcl-2 and Bcl-xL (38) . Here, we show that in mice with CAC, PHB suppresses colonic tumor formation in association with increased rates of apoptosis. In human colon cancer cells, PHB interacts with p53 and phospho-STAT3 and modulates their downstream apoptotic proteins. These findings suggest that PHB protects against CAC by modulating p53 and STAT3 apoptotic responses.
The best-characterized function of PHB is as a chaperone involved in the stabilization of mitochondrial proteins thereby maintaining normal mitochondrial function and morphology (reviewed in (39)). In most cell types studied, including intestinal epithelial cells, PHB is predominantly localized to the mitochondria (9). However, it has been localized to the cell membrane, cytoplasm, or the nucleus in some cell types (6, 40, 41) . Although PHB expression is increased in many transformed cells and tumors (13) (14) (15) (16) (17) (18) (19) , in our study, colonic mucosal PHB protein expression was reduced after the development of colitis-associated tumors in WT mice. (23), and liver cancer (22) . Mice with hepatocyte-specific deletion of PHB exhibited liver injury, fibrosis, oxidative stress and hepatocellular carcinoma developing by 8 months of age (22) . Mitochondrial abnormalities in hepatocytes are evident by 3 weeks of age including no cristae formation (22) . Knockdown of PHB expression by siRNA in Caco2-BBE intestinal epithelial cells caused mitochondrial depolarization and increased intracellular reactive oxygen species (27) . Interestingly, mitochondrial dysfunction is a common feature of cancer cells and multiple studies suggest that mitochondrial chaperone proteins, including PHB, modulate tumorigenesis (reviewed in (42)).
A functional role for PHB as a regulator of transcription has become evident due to its interactions with p53, E2F and Rb (6, 7, 43) . Here, we show that in addition to p53, PHB interacts with STAT3 in vitro and in vivo. Studies in breast cancer, prostate cancer, and retinal pigment epithelial cell lines indicate that PHB increases the transcriptional activity and prevents denaturation of p53, thereby regulating apoptosis (44) (45) (46) . Our study showed that PHB suppresses colonic tumor formation in association with increased rates of apoptosis and p53 apoptotic responses. Sequencing of exons 5, 6, 7 and 8 of p53 from DNA isolated from areas of dysplasia from 5 WT and 5 Tg mice found no mutations. Unlike human UC-associated cancers, DSS-induced colon tumors in mice do not commonly harbor p53 mutations (26) . Therefore, it is likely that the increased p53 in Tg mice is functional, unlike the increased, but mutant p53, in human IBD patients. PHB interaction with phospho-STAT3 was associated with decreased Bcl- 
xL and Bcl-2 expression in cultured intestinal epithelial cells and colon mucosa. The localization of PHB in the mitochondria and nucleus makes it an ideal candidate to modulate the mitochondrial apoptotic pathway and transcription activation. Further studies will assess the mechanism of PHB modulation of STAT3 signaling. PHB interacts with p53 and STAT3 in colon mucosa from mice treated with DSS alone without AOM injection (Supplemental Figure   1E ), suggesting interaction is not dependent upon the presence of tumors. Furthermore, Tg mice treated with DSS alone without AOM injection exhibited altered mucosal p53, PUMA, Bcl-2 and Bcl-xL protein expression (Supplemental Figure 1F) . Since the development of CAC is dependent on the severity of chronic inflammation, PHB transgene expression likely decreases the occurrence of CAC by decreasing the severity of DSS-induced inflammation and enhancing p53-mediated apoptosis and inhibiting STAT3 induction of anti-apoptotic genes during tumor formation. Early loss of PHB expression during inflammation may make genetically compromised intestinal epithelial cells more resistant to cell death, thereby promoting tumorigenesis.
In conclusion, PHB suppresses colonic tumor formation in association with increased rates of apoptosis in mice with colitis-associated cancer. PHB interacts with p53 and phospho- anti-Bax, and (E) anti-phospho-Bad and anti-Bad. Anti-β-actin was used as a loading control.
Histograms show cumulative mean band densitometry ± SEM, respectively. n ≥ 5 per treatment. *P < 0.05, **P < 0.01. 
